Effect of Genome Size on AAV Vector Packaging

Slides:



Advertisements
Similar presentations
Clinical Laboratory Analysis of Immunoglobulin Heavy Chain Variable Region Genes for Chronic Lymphocytic Leukemia Prognosis  Philippe Szankasi, David.
Advertisements

Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 8, Issue 1, Pages (July 2003)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
The Mre11 Complex Is Required for Repair of Hairpin-Capped Double-Strand Breaks and Prevention of Chromosome Rearrangements  Kirill S. Lobachev, Dmitry.
Volume 19, Issue 4, Pages (August 2005)
Molecular Therapy - Methods & Clinical Development
Robert E. White, Richard Wade-Martins, Michael R. James 
Volume 16, Issue 3, Pages (March 2008)
Volume 17, Issue 8, Pages (August 2009)
Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy  Masahito Ikawa, Nobushige.
Improved system for helper-dependent adenoviral vector production
Claire Soudais, Sylvie Boutin, Eric J. Kremer  Molecular Therapy 
Volume 61, Issue 1, Pages S9-S15 (January 2002)
Volume 10, Issue 1, Pages (July 2004)
Transduction of Human Embryonic Stem Cells by Foamy Virus Vectors
Clinical Laboratory Analysis of Immunoglobulin Heavy Chain Variable Region Genes for Chronic Lymphocytic Leukemia Prognosis  Philippe Szankasi, David.
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Molecular Therapy - Methods & Clinical Development
Vaccinia virus as a subhelper for AAV replication and packaging
Molecular Therapy - Methods & Clinical Development
A Rad51 Presynaptic Filament Is Sufficient to Capture Nucleosomal Homology during Recombinational Repair of a DNA Double-Strand Break  Manisha Sinha,
Volume 18, Issue 6, Pages (June 2010)
Molecular Therapy - Methods & Clinical Development
A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae  Yang Wu, Liangyu Jiang,
Jung-Ok Han, Sharri B Steen, David B Roth  Molecular Cell 
Volume 2, Issue 3, Pages (September 2000)
Helper virus-mediated downregulation of transgene expression permits production of recalcitrant helper-dependent adenoviral vector  Donna J Palmer, Nathan.
Volume 19, Issue 3, Pages (March 2011)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Xiuwu Zhang, Chuan-Yuan Li  Molecular Therapy 
Retroviral vector–mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells  Daryoush.
547. AAV Preparations Contain Contamination from DNA Sequences in Production Plasmids Directly Outside of the ITRs  Mark A. Brimble, Junfang Zhou, Christopher.
Volume 23, Issue 10, Pages (October 2015)
Volume 8, Issue 1, Pages (July 2003)
Kailin Xu, Hong Ma, Thomas J. McCown, Inder M. Verma, Tal Kafri 
Frpo: A Novel Single-Stranded DNA Promoter for Transcription and for Primer RNA Synthesis of DNA Replication  Hisao Masai, Ken-ichi Arai  Cell  Volume.
Volume 16, Issue 5, Pages (May 2008)
Volume 16, Issue 6, Pages (June 2008)
Molecular Therapy - Nucleic Acids
Volume 15, Issue 2, Pages (February 2007)
Volume 19, Issue 4, Pages (April 2011)
Volume 25, Issue 2, Pages (February 2017)
Mathieu Nonnenmacher, Harm van Bakel, Roger J Hajjar, Thomas Weber 
Volume 22, Issue 4, Pages (April 2014)
Efficient Sleeping Beauty DNA Transposition From DNA Minicircles
Template Switching by RNA Polymerase II In Vivo
Volume 18, Issue 3, Pages (March 2010)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Cheryl A. Carlson, Dmitry M. Shayakhmetov, André Lieber 
Volume 4, Issue 6, Pages (December 2001)
Volume 17, Issue 1, Pages (January 2009)
Volume 6, Issue 3, Pages (September 2002)
Volume 18, Issue 1, Pages (January 2003)
Volume 18, Issue 6, Pages (June 2010)
Molecular Therapy - Methods & Clinical Development
Volume 15, Issue 7, Pages (July 2007)
Molecular Therapy - Methods & Clinical Development
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia  Marie Reine Haddad, Anthony.
Volume 20, Issue 6, Pages (June 2012)
Volume 7, Issue 1, Pages (January 2003)
Zhijian Wu, Aravind Asokan, R. Jude Samulski  Molecular Therapy 
Thomas Gaj, Benjamin E Epstein, David V Schaffer  Molecular Therapy 
Evidence for Encapsidation of Prokaryotic Sequences during Recombinant Adeno- Associated Virus Production and Their in Vivo Persistence after Vector Delivery 
High-level production of replication-defective human immunodeficiency type 1 virus vector particles using helper-dependent adenovirus vectors  Yani Hu,
Biao Dong, Hiroyuki Nakai, Weidong Xiao  Molecular Therapy 
Volume 3, Issue 4, Pages (April 2001)
Molecular Therapy - Methods & Clinical Development
Xiaorong Wang, Peter Baumann  Molecular Cell 
Presentation transcript:

Effect of Genome Size on AAV Vector Packaging Zhijian Wu, Hongyan Yang, Peter Colosi  Molecular Therapy  Volume 18, Issue 1, Pages 80-86 (January 2010) DOI: 10.1038/mt.2009.255 Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Electrophoresis of AAV-mCEP290 vectors. (a) Structure of the AAV mouse CEP290 vector. (b) Alkaline agarose electrophoresis and Southern blot analysis of isolated AAV mCEP290 vector genomes. Lanes 1 and 2: 8,343 bp vector plasmid DNA marker, 0.1 and 1 ng, respectively; lanes 3 and 4: 5,067 bp vector plasmid DNA marker, 0.1 and 1 ng, respectively; lanes 5–7: DNA from 1 × 1010 vector genomes isolated from AAV2 mCEP290, AAV5 mCEP290, and AAV8 mCEP290 vector preparations, respectively. AAV, adeno-associated virus; bp, base pair; CMV, cytomegalovirus; ITR, inverted terminal repeat; kb, kilobase. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Genome integrity of AAV5-mCEP290 vector. (a) Hybridization positions of single-stranded oligonucleotides on the vector genome. (b) Strand-specific dot-blot hybridization of vector genome DNA. Twofold serial dilutions of vector plasmid DNA (top row) and isolated AAV5 mCEP290 vector genome DNA (bottom row). The masses of the vector plasmid DNAs are 50, 25, 12.5, 6.25, 3.1, 1.6, 0.78, and 0.39 ng (wells 1–8, top row). The calculated masses of the isolated vector DNAs are 7, 3.5, 1.7, 0.86, 0.43, 0.21, 0.11, and 0.05 ng (wells 1–8, bottom row). The DNA in the first well on the bottom row was isolated from 2.3 × 109 vector genomes. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Packaging of AAV2 and AAV5 lacZ vectors. (a) Structures of plasmid-encoded vectors ranging from 4.7 to 8.7 kb. All of these vectors contained a 4.4 kb CMV lacZ expression cassette, located adjacent to the ITR (I designation in name) or centrally (C designation in name), and phage lambda DNA was used to increase the total length. (b) Southern blot analysis of isolated vector genome DNA separated on an alkaline agarose gel. 1 × 1010 vector genomes were analyzed for the AAV5 vectors (upper panel), and 1 × 109 vector genomes were analyzed for the AAV2 vectors (lower panel). Vector plasmid DNA markers in lanes M1: 8.6 kb (1 ng), M2: 5.1 kb (1 ng), M3: 8.6 kb (0.1 ng), and M4 5.1 kb (0.1 ng). The DNA in M2 is an unintended partial digestion. Lanes 1–8 in both panels: genomes isolated from AAV-lacZ-4.7k, AAV-lacZ-I5.2k, AAV-lacZ-I5.7k, AAV-lacZ-I6.7k, AAV-lacZ-I8.7k, AAV-lacZ-C5.7k, AAV-lacZ-C6.7k, and AAV-lacZ-C8.7k vector preparations, respectively. CMV, cytomegalovirus; ITR, inverted terminal repeat; kb, kilobase. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 LacZ expression in 293 cells infected with AAV2-lacZ vectors. (a) LacZ expression in 293 cells infected with AAV2-lacZ vectors at MOI 2,000 (left panels) or 10,000 (right panels). (b) Quantification of transduction of the AAV2 lacZ vector set. MOI, multiplicity of infection. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Proposed model for packaging and transduction of AAV2 lacZ vectors. (1) Packaging, (2) uncoating, (3) second-strand DNA synthesis, (4) annealing, and (5) homologous recombination. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Proposed model for fragmentary genome transduction. Right panel: one ITR and intact lacZ cassette contained in DNA fragment <5,050 bp in length. Left panel: intact lacZ cassette and either ITR contained in a DNA fragment >5,050 bp in length. The higher transduction efficiency of vectors with ITR-proximal lacZ expression cassettes may indicate that these vectors package the first 5,050 bp from the 3′ end, which encodes one ITR and an intact lacZ expression, and that this fragmentary genome is capable of mediating gene expression without having to anneal to a second vector. bp, base pair; CMV, cytomegalovirus; ITR, inverted terminal repeat. Molecular Therapy 2010 18, 80-86DOI: (10.1038/mt.2009.255) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions